Blueprint Medicines Co. Forecasted to Earn Q2 2026 Earnings of $0.33 Per Share (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Stock analysts at Zacks Research upped their Q2 2026 earnings estimates for shares of Blueprint Medicines in a research report issued on Monday, September 16th. Zacks Research analyst A. Chakraborty now anticipates that the biotechnology company will earn $0.33 per share for the quarter, up from their previous forecast of $0.31. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.99) per share.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The company had revenue of $138.20 million during the quarter, compared to analyst estimates of $104.02 million. During the same period in the previous year, the business posted ($2.19) earnings per share. The firm’s quarterly revenue was up 139.9% compared to the same quarter last year.

Other analysts have also recently issued research reports about the company. Baird R W upgraded Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. Oppenheimer raised their target price on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, July 8th. Robert W. Baird upped their price target on shares of Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Morgan Stanley increased their price objective on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Finally, JMP Securities restated a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, June 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Blueprint Medicines Trading Up 1.8 %

Shares of BPMC stock opened at $90.94 on Thursday. Blueprint Medicines has a 1 year low of $43.89 and a 1 year high of $121.90. The firm has a fifty day moving average price of $98.82 and a 200-day moving average price of $99.01. The company has a market cap of $5.69 billion, a price-to-earnings ratio of -18.91 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65.

Insider Transactions at Blueprint Medicines

In related news, insider Debra Durso-Bumpus sold 333 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $111.15, for a total value of $37,012.95. Following the completion of the transaction, the insider now directly owns 43,763 shares of the company’s stock, valued at $4,864,257.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Debra Durso-Bumpus sold 333 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $111.15, for a total value of $37,012.95. Following the completion of the transaction, the insider now owns 43,763 shares of the company’s stock, valued at approximately $4,864,257.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Philina Lee sold 41,913 shares of Blueprint Medicines stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the transaction, the insider now owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. The disclosure for this sale can be found here. Insiders have sold 54,913 shares of company stock valued at $5,352,249 in the last ninety days. Corporate insiders own 4.21% of the company’s stock.

Institutional Trading of Blueprint Medicines

A number of institutional investors have recently bought and sold shares of BPMC. Triad Wealth Partners LLC bought a new position in Blueprint Medicines during the second quarter valued at $27,000. Covestor Ltd grew its holdings in Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 291 shares during the last quarter. Headlands Technologies LLC raised its position in Blueprint Medicines by 105.2% in the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 342 shares during the period. Natixis bought a new stake in Blueprint Medicines in the first quarter worth about $73,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Blueprint Medicines in the fourth quarter worth about $95,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.